← Return to all swing-trade opportunities
RMD — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 20.0/100
Why this was flagged
RMD was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 20.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found Resmed Inc (RMD) using a pattern called an Oversold Bullish Reversal. This means the price dropped quickly, and the Relative Strength Index (RSI) is at 29.82. RSI is a tool used to see if a stock has been sold too much. When the RSI is low, it can suggest the selling might be finishing. The scanner gave this setup a score of 20 out of 100 based on its rules for price and volume.
What the price plan means
The entry zone is between $195.27 and $196.93. If you enter here, there are two target prices where the price might go: $208.70 and $215.42. To manage risk, a stop-loss price of $188.55 is set. This is a price point used to exit if the stock moves in the wrong direction. The reward-to-risk ratio is 2, which compares the potential gain to the potential loss.
What could make the idea fail
The setup might not work if the price continues to drop below the stop-loss level of $188.55. Also, the relative volume is only 0.66, which means there is less trading activity than usual. Low volume can mean there is not enough interest to push the price up.
Important reminder
This information is for educational purposes only and does not constitute financial advice.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (High confidence)
ResMed Inc (RMD) recently reported strong Q3 2024 financial results, with earnings per share of $37.29 and revenue of $20.96 billion, both exceeding market expectations. The company demonstrated a 7.17% year-over-year revenue growth. Following a five-day losing streak, the stock recently outperformed the broader market. Several analysts, including those from J.P. Morgan and Canaccord Genuity, have maintained 'Buy' ratings on the stock, although Morgan Stanley and Citi maintain neutral or hold positions.
Potentially supportive context
- Q3 2024 EPS of $37.29 beat the consensus estimate of $33.74.
- Revenue of $20.96 billion surpassed expectations and grew 7.17% year-over-year.
- Multiple analysts, including J.P. Morgan and Canaccord Genuity, maintain 'Buy' ratings.
Risks and caution items
- Morgan Stanley and Citi have maintained Hold or Neutral ratings on the stock.
- Historical data shows a previous Q1 revenue miss, despite year-over-year growth.
Latest reviewed article: Jul 25, 2026 12:39 am
Recent related articles
Resmed Inc (RMD) announced its Q3 2024 earnings, reporting actual EPS of $37.29, beating the consensus of $33.74, and actual revenue of $20.96 billion, surpassing the expected $20.56 billion. The revenue marked a significant 7.17% year-over-year growth. The company has also provided…
ResMed Inc. (RMD) shares rose 1.76% to $195.27 on Friday, breaking a five-day losing streak and outperforming the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average also saw gains during the trading session. This positive movement for…
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial…
J.P. Morgan maintained its Buy rating on Resmed Inc (RMD) with a price target of A$35.80, reiterating a positive outlook for the company. This follows Resmed's recent strong financial performance, reporting a quarterly revenue of A$1.42 billion and a net profit of…
Resmed Inc. (0KW4) reported its Q1 2024 earnings, beating the consensus EPS estimate by $0.02 with an actual EPS of $1.64. The company's revenue, however, slightly missed expectations at $1.10 billion, but still represented a 16.00% year-over-year growth. The report includes details…
This Yahoo Finance page provides detailed stock information for Perrigo Company plc (PRGO), including its current stock price, recent trading activity, key financial metrics, and performance over various periods. It also offers an overview of the company's business segments and products, analyst…
Canaccord Genuity analyst Shane Storey has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$40.00. This comes after the company reported strong financial results, with quarterly revenue of A$1.42 billion and a net profit…
This article analyzes the valuations of Abbott Laboratories (ABT), Boston Scientific (BSX), and ResMed (RMD) within the medical device industry. It highlights that ABT trades at a premium despite slower growth compared to BSX, which offers faster growth at a lower price.…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- RSI is near oversold territory with bullish candle confirmation.